Alliance Global Partners upgraded shares of Organigram (NASDAQ:OGI – Free Report) from a neutral rating to a buy rating in a report published on Monday, MarketBeat.com reports.
Organigram Price Performance
OGI opened at $1.87 on Monday. The stock has a market capitalization of $192.98 million, a PE ratio of -2.34 and a beta of 1.09. The firm’s fifty day moving average price is $2.10 and its 200 day moving average price is $1.62. Organigram has a 12-month low of $0.97 and a 12-month high of $2.91.
Organigram (NASDAQ:OGI – Get Free Report) last issued its earnings results on Tuesday, February 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). The business had revenue of $26.78 million for the quarter, compared to analyst estimates of $28.61 million. Organigram had a negative return on equity of 30.94% and a negative net margin of 173.48%. On average, equities research analysts forecast that Organigram will post -0.26 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Organigram
About Organigram
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Featured Stories
- Five stocks we like better than Organigram
- Bank Stocks – Best Bank Stocks to Invest In
- Comprehensive PepsiCo Stock Analysis
- What is Short Interest? How to Use It
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.